MKI67 and large cell neuroendocrine carcinoma: Grade 3 AEs occurred in 70% of patients; no grade 4 AEs were observed.<h4>Conclusions</h4>The MAVERIC trial demonstrated encouraging clinical benefit of everolimus in metastatic GEP-NEN and LCNEC (Ki-67 20%-55%) following first-line CT.